Skip to content
PeptideAI
Animal data onlyhealingjoint tendongut healthrecovery

BPC-157 Arginate

The arginine-salt form of BPC-157, sold because it holds up far better in solution and at room temperature than the usual acetate salt.

Also known as Arginate salt BPC-157, BPC-157 ARG, Stable BPC, BPC-157 arginine salt

Animal data only — Rodent or other animal studies. Dose translation to humans is genuinely uncertain.

All of the efficacy evidence is borrowed from the BPC-157 rodent literature. The stability advantage of the arginate salt is chemically reasonable and supported by supplier stability data, but there is no peer-reviewed human comparison of the two salt forms.

How it works

The active moiety here is the same 15-amino-acid peptide as BPC-157; only the counter-ion differs. Arginate salts of peptides generally show better aqueous solubility and slower degradation than acetate salts, which is the practical difference people are buying. Vendors label these products by peptide-base mass, so 5 mg on the label means 5 mg of peptide, and the quoted 1419.5 Da is the free-peptide mass rather than the salt. There is no published pharmacokinetic comparison in humans between the two salts, and no evidence that the arginate form does anything pharmacologically different once it is in the body.

Targets: VEGFR2, Nitric oxide / eNOS pathway, FAK-paxillin signalling, EGR-1 / NAB2

Dosing

ProtocolDoseFrequencyRoute
Standard systemic protocolSplit morning and evening or dosed once daily.250 mcg – 500 mcgonce or twice dailysubcutaneous
Oral protocol for gut targetsEmpty stomach, usually on waking.500 mcg – 1 mgonce dailyoral
  • · Dose milligram-for-milligram with acetate BPC-157; there is no accepted conversion factor because vendors label by peptide base.
  • · The stability argument is strongest here - an arginate solution sitting in a fridge for a month degrades less than acetate does.

Cycling

Four to eight weeks on, then a break, exactly as with acetate BPC-157.

Work out your exact syringe units →

Pharmacology

Half-life
Not established in humans. Assume the same short plasma presence as acetate BPC-157; the salt affects shelf stability, not clearance.
Onset
Same as BPC-157 - gut effects within about a week, connective tissue effects judged over two to six weeks.
Routes
subcutaneous, oral, intramuscular
Molecule
Synthetic pentadecapeptide, arginine salt
Sequence length
15 amino acids
Molecular weight
1419.5 Da

Handling

Diluent
Bacteriostatic water
Typical mix
2 or 3 mL
Vial sizes
5, 10, 20 mg
Lyophilised
Comfortable at room temperature for weeks; fridge or freezer for long-term storage.
Reconstituted
Refrigerated; commonly used for 30-60 days, which is the practical selling point over acetate.
Light sensitive
Yes — keep it out of the light

Mixing

Dissolves readily and tolerates a longer time in solution than the acetate salt, but it is still a sterile-handling job - swirl, do not shake.

Side effects

  • commonInjection-site stinging or redness— Often reported as milder than the acetate form, though that is anecdote rather than data.
  • uncommonHeadache
  • uncommonTransient fatigue in the first few days

Do not use if

  • Active or recently treated malignancy - the same angiogenesis concern that applies to BPC-157 applies here.
  • Undiagnosed structural injury - imaging first, peptides second.

Combining it

  • redundantbpc-157 — Same active peptide; running both is just splitting one dose across two vials.
  • synergytb-500 — The standard soft-tissue pairing.

What to monitor

  • · No established bloodwork.
  • · Track the injury with a repeatable loading test rather than by feel.

Legal status

Not approved for human use in the US or EU. Sold as a research chemical and, in the US, through some compounding pharmacies whose regulatory footing is currently unsettled after the July 2026 advisory committee vote on BPC-157.

References

  • Sikiric et al., stable gastric pentadecapeptide BPC 157 review series (review)
  • FDA Pharmacy Compounding Advisory Committee, July 2026 briefing materials on BPC-157 free base and salt forms (guideline)

Mechanism in depth

There is no separate mechanism to describe. The arginate is the same fifteen residues as BPC-157 with arginine as the counter-ion instead of acetate, and once it is in solution and then in tissue the pharmacology is BPC-157's - VEGFR2 upregulation into Akt-eNOS, FAK-paxillin driven fibroblast migration, EGR-1/NAB2 induction, growth hormone receptor upregulation on tendon fibroblasts. What the counter-ion genuinely changes is chemistry outside the body. Peptide acetate salts hydrolyse and aggregate faster in aqueous solution than arginate salts do, and acetate is more hygroscopic in the lyophilised state. That translates into a longer usable window for a reconstituted vial sitting in a fridge, which is a real and testable advantage - it is just an advantage in your fridge, not in your tendon. One thing worth understanding is the arginine itself. At the doses involved - a few hundred micrograms of peptide - the arginine counter-ion contributes a trivially small amount of free arginine, far below anything that would meaningfully feed the nitric oxide pathway. Anyone telling you the arginate form 'adds NO substrate synergy' has not done the arithmetic.

What usually goes wrong

The main failure mode here is paying a premium for a stability advantage you are not actually using. If you reconstitute a 5 mg vial and finish it in ten days, the acetate salt will not have degraded meaningfully and the arginate has bought you nothing. The second is dosing confusion. Salt-form products can be labelled by peptide base mass or by total salt mass, and the difference is on the order of ten to fifteen percent. Most reputable vendors label by base, but 'most' is doing a lot of work in an unregulated market. Check the certificate of analysis before assuming your 250 mcg is 250 mcg of peptide. The third is the assumption that a stability upgrade means a potency upgrade. It does not. Nothing about the arginate salt makes the peptide work better once it is dissolved in you.

Bloodwork worth running

MarkerWhenWhy it matters
hs-CRPBaseline and four to six weeks.Same rationale as BPC-157 - the only cheap objective read on a systemic inflammatory process.Act if: No movement at six weeks alongside no symptomatic change means stop.

Pharmacokinetics

Metabolism
Identical to BPC-157 - peptidase hydrolysis to fragments and then free amino acids.
Elimination
Urine and bile.

Receptor targets

  • VEGFR2 (KDR) — No binding constant published, as for BPC-157 acetate

    Same angiogenic cascade - receptor upregulation and phosphorylation into Akt-eNOS.

  • eNOS / nitric oxide system — Not a receptor interaction

    Same bidirectional stabilising effect on vascular tone.

  • FAK-paxillin focal adhesion complex — Not characterised

    Same fibroblast migration effect in tendon tissue.

What to expect, and when

Identical to BPC-157. Gut effects at three to seven days, connective tissue judged at two to six weeks, decision point at week six. The salt form does not change onset because it does not change clearance.

Stacking and comparisons

Everything in the BPC-157 stacking notes applies unchanged. The one addition specific to this form: do not run it alongside acetate BPC-157 thinking you are combining two compounds. You are taking one compound out of two vials at twice the price. The practical case for choosing the arginate is a long oral course, where a reconstituted solution sits in a fridge for a month or more between doses and acetate degradation is a genuine loss of potency over that window.

Against acetate BPC-157: same molecule, better shelf and solution stability, higher price. The stability difference is chemically real and supported by supplier data but has never been quantified in a peer-reviewed head-to-head. Choose arginate if you are running long oral courses or storing a reconstituted vial for over a month; choose acetate if you are finishing vials quickly and want the cheaper unit. Against pentadeca arginate: these are the same product under two names. Any price gap between them is a naming premium.

Rough cost

$35–$120/month. Order-of-magnitude estimate from grey-market pricing, typically a modest premium over acetate BPC-157. Not price-checked in the preparation of this entry.

Genuinely uncertain

  • No published pharmacokinetic, potency or stability comparison between the arginate and acetate salts in any species. The stability advantage rests on general peptide salt chemistry and supplier data, not peer review.
  • Whether a given vial is labelled by peptide base mass or total salt mass varies by vendor and is often not stated.
  • All efficacy evidence is inherited from acetate BPC-157 rodent work; nothing has been tested on the arginate form specifically.
  • Cost figures are estimates and were not price-verified in this session.

Papers